Barclays PLC Chroma Dex Corp. Transaction History
Barclays PLC
- $357 Billion
- Q4 2024
A detailed history of Barclays PLC transactions in Chroma Dex Corp. stock. As of the latest transaction made, Barclays PLC holds 79,773 shares of CDXC stock, worth $432,369. This represents 0.0% of its overall portfolio holdings.
Number of Shares
79,773
Previous 70,072
13.84%
Holding current value
$432,369
Previous $256,000
65.23%
% of portfolio
0.0%
Previous 0.0%
Shares
25 transactions
Others Institutions Holding CDXC
# of Institutions
129Shares Held
21.9MCall Options Held
203KPut Options Held
23.9K-
Vanguard Group Inc Valley Forge, PA3.39MShares$18.4 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.12MShares$16.9 Million0.0% of portfolio
-
Tieton Capital Management, LLC Yakima, WA2.59MShares$14 Million5.52% of portfolio
-
Iconiq Capital, LLC San Francisco, CA1.3MShares$7.03 Million0.14% of portfolio
-
Geode Capital Management, LLC Boston, MA1.15MShares$6.26 Million0.0% of portfolio
About ChromaDex Corp.
- Ticker CDXC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 68,350,896
- Market Cap $370M
- Description
- ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingre...